| 摘要 |
The present invention relates to transferrin, possibly in combination with an iron-chelator (e.g. deferoxamine) or a PHD2 enzyme inhibitor, for use in the treatment of Hypoxia Inducible Factor (HIF)-related conditions, in particular associated with organ transplantation, ischemia, oxygen deprivation, interruption of blood during surgical intervention, or neurodegenerative disorders. |
